<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="Tab2">
 <label>Table 2</label>
 <caption>
  <p>Anti-SARS-CoV-2 drugs and its rheumatic musculoskeletal adverse effects</p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left">Drugs</th>
    <th align="left">Antiviral mechanisms</th>
    <th align="left">Rheumatic musculoskeletal adverse events</th>
    <th align="left">Refs.</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left">Chloroquine and hydroxychloroquine</td>
    <td align="left">Inhibit pH-dependent internalization and fusion of the virus with lysosomes</td>
    <td align="left">Myopathy and neuromyopathy</td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR33">33</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Favipiravir</td>
    <td align="left" rowspan="3">Inhibit viral RNA-dependent RNA polymerase</td>
    <td align="left">Hyperuricemia</td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR34">34</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Remdesivir</td>
    <td align="left">Not reported</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">EIDD-2801</td>
    <td align="left">Not reported</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Lopinavir-ritonavir</td>
    <td align="left">Protease inhibitor</td>
    <td align="left">Hyperuricemia (≤ 5%), musculoskeletal pain (6%), arthralgia (&lt; 2%), osteonecrosis, vasculitis, SJS-TEN</td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR35">35</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Umifenovir</td>
    <td align="left">Block the virus-cell membrane fusion as well as virus-endosome fusion</td>
    <td align="left">Not reported</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Galidesivir</td>
    <td align="left">Antiviral adenosine nucleoside analog</td>
    <td align="left">Not reported</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Ribavirin</td>
    <td align="left">Interfere with polymerases, RNA capping, and inosine monophosphate dehydrogenase</td>
    <td align="left">
     <p>Arthralgia (&gt; 10%), musculoskeletal pain (&gt; 10%), backache (1–10%),</p>
     <p>gout (&lt; 1%), myositis (&lt; 1%),</p>
     <p>Exacerbation of sarcoidosis (higher incidence in combination with interferon α)</p>
    </td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR36">36</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Camostat mesylate</td>
    <td align="left">Serine protease inhibitor</td>
    <td align="left">Not reported</td>
    <td align="left"/>
   </tr>
   <tr>
    <td align="left">Interferon α and β</td>
    <td align="left" rowspan="2">Inhibit replication</td>
    <td align="left">
     <p>Interferon α2b:</p>
     <p>Myalgia (16–75%), musculoskeletal pain (1–21%), arthralgia (3–19%), backache (1–19%), amyotrophy (&lt; 5%),</p>
     <p>Arthritis (&lt; 5%) including RA,</p>
     <p>Other autoimmune disease (&lt; 1%) including sarcoidosis, myositis, rhabdomyolysis, SJS, SLE, vasculitis</p>
     <p>Interferon β1a and β1b:</p>
     <p>Myalgia (25–29%),</p>
     <p>Backache (23–25%),</p>
     <p>Autoimmune hepatitis,</p>
     <p>Immune thrombocytopenia, SLE, osteonecrosis, Sjogren syndrome</p>
    </td>
    <td align="left">[
     <xref ref-type="bibr" rid="CR37">37</xref>]
    </td>
   </tr>
   <tr>
    <td align="left">Convalescent plasma</td>
    <td align="left">
     <p>Chance of transfusion-related adverse events: urticaria, anaphylaxis, transfusion-related acute lung injury</p>
     <p>Latent risk of hyperimmune attacks:</p>
     <p>Possibly via antibody-dependent enhancement of tissue damage and blunting of endogenous immunity to the virus</p>
    </td>
    <td align="left"/>
   </tr>
  </tbody>
 </table>
 <table-wrap-foot>
  <p>
   <italic>RNA</italic> ribonucleic acid, 
   <italic>SJS-TEN</italic> Steven Johnson syndrome-toxic epidermal necrolysis, 
   <italic>SLE</italic> systemic lupus erythematosus
  </p>
 </table-wrap-foot>
</table-wrap>
